Trevi Therapeutics, Inc. (TRVI)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Trevi Therapeutics: Full Filing Text is Required for Analysis
I am unable to summarize the filing because the actual document content was not provided. The structured tags indicated a filing (`<PDF></PDF>`) but contained no text or data. Please provide the full text, or the PDF of, the SEC filing for Trevi Therapeutics, Inc. (TRVI). Once I receive the documen
TRVI proposes doubling authorized shares and expanding incentive stock pool
# 📑 What This Document Is 📰 This document is a Definitive Proxy Statement, which is essentially an official packet of instructions for the company's annual meeting. 👉 It tells stockholders exactly what topics will be voted on, who the leaders are, and how they must vote their shares. The filing d
Trevi Therapeutics TRVI Seeks Approval for Stock Plan and Share Increase
# 🧾 What This Document Is This is a **PRE 14A**, or **Preliminary Proxy Statement**. Think of it as a "preview" and an invitation. Trevi Therapeutics is sending it to its shareholders ahead of the **2026 Annual Meeting**. Its job is to explain what will be voted on, provide background info, and rec
SEC filings
All filings →Insider trades
All insider trades →Trevi Therapeutics, Inc. has no reported insider trades in the last 90 days.